Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?

Haematologica. 2020 Dec 1; 105(12): 2738–2745.
Published online 2020 Oct 9. doi: 10.3324/haematol.2019.242891

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
Ehab Atallah1 and Charles A Schiffer2

'....An attempt at treatment discontinuation should be considered the standard of care for patients with CML who have a sustained DMR. Realistically, only 40-50% of newly diagnosed patients with CML will achieve this threshold, and only half of those (~20% of all patients) will achieve a successful TFR. These estimates are extrapolated from the results of clinical trials and may overstate the actual number of patients treated in general practice who may achieve the required depth and duration of response and be eligible for a trial of TKI discontinuation. Many unanswered questions remain. How can we better identify patients who will achieve DMR and TFR?...'

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716356/